文献速递前列腺增生与排尿功能障碍

良性前列腺增生内镜术后阿片类药物处方模式及变异驱动因素评估

Evaluation of Opioid Prescribing Patterns and Drivers of Variation Following Endoscopic Procedures for Benign Prostatic Hyperplasia Across an Integrated Academic Health System.
PubMed 文献 · Urology · 2021-01-19

本研究在大型学术医疗系统内回顾性分析724例良性前列腺增生内镜手术患者,评估出院阿片处方的患者、医生和机构层面变异。结果显示30.7%患者接受阿片处方,不同术者(0%-88.9%)和机构(19.9%-66.7%)间差异显著;门诊手术和术前阿片使用与更高处方率相关。

要点

  • 内镜前列腺术后阿片处方率30.7%,术者间差异大(0%-88.9%)。
  • 门诊手术(OR 2.32)和术前阿片使用(OR 15.04)与更高处方率相关。
  • 年轻患者处方率更高(OR 0.97/岁),卫星机构手术和资深术者与更高MME相关。

核心结论

  • 良性前列腺增生内镜术后阿片处方存在广泛变异,患者、术者和机构因素均与变异相关。

主要发现

  • 222例(30.7%)患者接受阿片处方,平均处方吗啡毫克当量(MME)为97.9±33.5。
  • 术者间阿片处方比例范围为0%-88.9%,机构间为19.9%-66.7%,平均MME范围为25-188.5。
  • 患者年龄增加与处方率降低相关(OR 0.97;95%CI 0.95-0.99,P=0.016)。
  • 多变量线性回归显示卫星机构手术、术者执业至少20年和高手术量与更高MME处方相关。

临床怎么用

  • 针对年轻患者、术前使用阿片者、门诊手术患者及卫星机构手术患者开展靶向干预可能提高处方优化效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate patient, provider, and facility factors associated with variation in opioid prescribing after endoscopic procedures for benign prostatic hyperplasia across a large academic health system to drive improvement efforts. METHODS: Opioids prescribed at discharge for patients who underwent an endoscopic prostate procedure March 2018-November 2019 were analyzed. Multivariable logistic and linear regression were used to evaluate the relationship between patient, provider, and facility factors and the receipt of any opioid prescription and the quantity prescribed. RESULTS: We included 724 patients who had surgery with one of 26 urologists across five facilities. 222 (30.7%) received an opioid prescription, and the average morphine milligram equivalents (MMEs) prescribed was 97.9±33.5. We found wide variation in the proportion of patients who received an opioid prescription across surgeons (range 0%-88.9%) and facilities (range 19.9%-66.7%) and the average MMEs prescribed (range 25-188.5). Outpatient surgery (OR 2.32; 95% confidence interval [CI] 1.22-4.40, P = .010) and preoperative opioid use (OR 15.04; CI 9.65-23.45, P < .001) were associated with higher rates of opioid prescribing, while prescribing decreased with increasing patient age (OR 0.97; CI 0.95-0.99, P = 0.016). Multivariable linear regression analysis demonstrated an association between surgery at satellite facilities, having a surgeon in practice for at least 20 years, and higher surgeon volume with increased MMEs prescribed. CONCLUSIONS: Opioid prescribing following endoscopic prostate procedures varied widely. Targeted interventions tailored to younger patients, those taking opioids preoperatively, recipients of outpatient surgery and those undergoing surgery at satellite facilities may be particularly high yield given the association between these factors and increased postoperative prescribing.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Vo AX, Ko OS, Hofer MD, et al. Evaluation of Opioid Prescribing Patterns and Drivers of Variation Following Endoscopic Procedures for Benign Prostatic Hyperplasia Across an Integrated Academic Health System. Urology. 2021. PMID: 33482131. doi:10.1016/j.urology.2020.10.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。